Croce,chair of the Department of Cancer Biology and Genetics at The Ohio State University, shares this year’s award with two prominent researchers—Mary-Claire King, a professor of genome sciences and medicine at the University of Washington in Seattle, and Bert Vogelstein, a professor of oncology at Johns Hopkins School of Medicine in Baltimore.
What Caught Our Attention: We’ve found a fourth retraction for the unlicensed use of a common research tool, an issue we explored in depth for Science last year. Quick recap: When researchers use a copyrighted questionnaire (MMAS-8) without permission, they get a call from its creator Donald Morisky (or his representative), asking them to pay up — sometimes thousands of dollars. There’s another option: Retract the paper. That was the choice made by a group of researchers in Arkansas, who — in a nicely detailed notice — note that, since the scale was developed using federal funds, “they dispute the validity and reasonableness of Dr. Morisky’s demands in light of the National Institutes of Health’s Principles and Guidelines for Recipients of NIH Research Grants and Contracts on Obtaining and Disseminating Biomedical Research Resources.”Continue reading Caught Our Notice: Should publicly funded research tools be free for researchers to use?
Ever since critics began raising concerns about high-profile food scientist Brian Wansink’s work, he’s had to issue a series of high-profile retractions — and now has his seventh (including one paper that was retracted twice, after the journal removed a revised version, along with 14 corrections). The latest notice — first reported by BuzzFeed — is for a paper that was originally corrected by the journal Preventive Medicine earlier this month — and the correction notice was longer (1636 words) than the original, highly cited paper (1401 words). Following criticism by James Heathers about the highly cited study back in March 2017, the authors issued a series of changes, including explaining the children studied were preschoolers (3-5 years old), not preteens (8-11), as originally claimed. (They made that mistake once before, in another retracted paper.) But critics remained concerned. Yesterday, the journal retracted the paper. We spoke with editor Eduardo Franco of McGill University — who provided us with an advanced copy of an accompanying editorial, soon to be published — about the editorial processes behind the two notices, including the moment the journal knew the correction wouldn’t suffice.
Retraction Watch: You write that the initial decision to correct the paper came with “considerable intellectual agony.” Can you say why?
When the Proceedings of the National Academy of Sciencesretracted a gene therapy paper in December, it declared that some of the data had been falsified and mentioned a research misconduct investigation. But the notice said nothing about who was responsible.
Via a public records request, Retraction Watch has obtained investigation documents from the University of Florida, which show the focus had been narrowed down to two of the paper’s three co-first authors. But the investigation committee didn’t assign blame to either one. According to their final report, dated Oct. 24, 2016:
there was not enough direct evidence to either implicate or exonerate either of these individuals.
After the paper appeared in 2017, one critic lamented it contained “obviously fabricated” images, and asked the journal to retract it. Another suggested the presence of one image merited “an instant lifetime ban.”
The first comment about the paper appeared on PubPeer three months ago; earlier this month, the journal ACS Biomaterials Science & Engineering retracted the paper.
Our readers will likely know that the site has been having significant trouble for more than two weeks. Thanks for your patience, your offers to help, and for sticking with us during that time. We’re happy to say that we seem to have identified all of the various issues involved, and have solved them. Some of those fixes may mean that you’ll need to resubscribe to our email alerts, so keep reading (or skip over the vaguely technical stuff in the next few paragraphs if you’d rather). Continue reading Retraction Watch is back at full speed. Here’s what you need to do to make sure you’re seeing our content.
We seem to be past the worst of our technical issues, so thanks for your patience with us over the past few weeks. (Some of the fixes came at a cost, so we would be remiss if we did not ask readers to consider a donation to support our work.)
Yesterday, Mark Jacobson, a researcher at Stanford University who studies the future of renewable energy, announced he would drop a $10 million defamation suit over a paper published in the Proceedings of the National Academy of Sciences that was critical of his work. As we reported, the announcement came just two days after the District of Columbia Superior Court heard oral arguments about the case because the defendants — the National Academy of Sciences and Christopher Clack, who runs a data analysis company called Vibrant Clean Energy — had asked the court to dismiss the case.
What Caught Our Attention: When the New England Journal of Medicine (NEJM) publishes a correction that is more than a misspelling of a name, we take a look. When NEJM publishes a 500-word correction to the data in a highly cited article, we take notice. This study tested the effects of a drug to prevent blood loss in patients undergoing heart surgery; it’s been the subject of correspondence between the authors and outside experts. The correction involved tweaks — lots of tweaks — to the text and tables, which did not change the outcomes. Continue reading Caught Our Notice: Big journal, big correction